Migraine Cortical Hyperexcitability and Alzheimer's Disease Risk: Longitudinal Mechanism Study

Experiment Score: 80 | Rank: 96 | Category: Basic Mechanism | Disease: Migraine/AD

Key Question

Does chronic migraine with cortical hyperexcitability (evidenced by cortical spreading depression, CSD) increase the risk of [Alzheimer's disease](/diseases/alzheimers-disease) through specific molecular pathways (tau hyperphosphorylation, neuroinflammation, blood-brain barrier disruption), and can [CGRP](/mechanisms/cgrp-migraine-pathway)-targeted migraine therapies reduce AD risk? Observational studies show migraine is associated with a 50-70% increased dementia risk, but the mechanistic pathway is unknown.

Gap Addressed

Clinical studies consistently show migraine as a dementia risk factor[@migrainememory2023], but the mechanism is poorly understood. Three hypotheses exist:

Hyperexcitability pathway: Repeated CSD events drive tau phosphorylation through calcium dysregulation

Neurovascular pathway: Migraine-associated vascular dysfunction impairs Aβ clearance via glymphatic system

Neuroinflammation pathway: Recurrent migraine activates astrocytes and microglia chronically, driving neurodegeneration

No mechanistic study has tested these hypotheses with longitudinal biomarker data.

Validation Protocol

Phase 1: Longitudinal Biomarker Study (Cohort: 300 migraine patients, 150 matched controls, 5-year follow-up)

...

Experiment Score: 80 | Rank: 96 | Category: Basic Mechanism | Disease: Migraine/AD

Key Question

Does chronic migraine with cortical hyperexcitability (evidenced by cortical spreading depression, CSD) increase the risk of [Alzheimer's disease](/diseases/alzheimers-disease) through specific molecular pathways (tau hyperphosphorylation, neuroinflammation, blood-brain barrier disruption), and can [CGRP](/mechanisms/cgrp-migraine-pathway)-targeted migraine therapies reduce AD risk? Observational studies show migraine is associated with a 50-70% increased dementia risk, but the mechanistic pathway is unknown.

Gap Addressed

Clinical studies consistently show migraine as a dementia risk factor[@migrainememory2023], but the mechanism is poorly understood. Three hypotheses exist:

Hyperexcitability pathway: Repeated CSD events drive tau phosphorylation through calcium dysregulation

Neurovascular pathway: Migraine-associated vascular dysfunction impairs Aβ clearance via glymphatic system

Neuroinflammation pathway: Recurrent migraine activates astrocytes and microglia chronically, driving neurodegeneration

No mechanistic study has tested these hypotheses with longitudinal biomarker data.

Validation Protocol

Phase 1: Longitudinal Biomarker Study (Cohort: 300 migraine patients, 150 matched controls, 5-year follow-up)

Migraine characterization: Attack frequency, aura status, CSD frequency (measured by EEG biomarkers), CGRP levels, treatment history (triptans, gepants, monoclonal antibodies)

AD biomarker panel (baseline + annual):

• Blood: p-tau217, NfL, GFAP
• MRI: hippocampal volume, cortical thickness, white matter lesions
• CSF subset (n=100): Aβ42/40, total-tau, p-tau181

3. Cortical excitability assessment: Transcranial magnetic stimulation (TMS) measures of motor/threshold, EEG event-related potentials

Phase 2: Mechanistic Studies (Cellular + Animal)

CSD-tau phosphorylation link: Mouse model — repeated CSD induction in 5XFAD vs wild-type mice, measure tau phosphorylation at specific sites (Ser396, Thr231) over time

CGRP direct effects: Test whether CGRP or CGRP receptor activation drives tau phosphorylation in iPSC-derived neurons

Glymphatic impairment by CSD: Two-photon imaging of glymphatic clearance in mice with repeated CSD events

Phase 3: CGRP-Targeted Therapy Neuroprotective Effects

Retrospective cohort: Compare AD biomarker trajectories in migraine patients treated with:

• CGRP monoclonal antibodies (erenumab, fremanezumab, eptinezumab) vs
• Oral preventive medications (propranolol, topiramate, amitriptyline) vs
• No preventive treatment

2. Prospective pilot: 2-year pilot (n=60) with standardized CGRP mAb treatment vs standard care, measuring biomarker change

Model Systems

| System | Application | Strength | Limitation |
|--------|-------------|----------|------------|
| Human longitudinal cohort (450 pts) | Migraine-AD biomarker correlation | Direct clinical relevance | 5-year follow-up attrition |
| TMS + EEG excitability measures | Objective hyperexcitability quantification | Non-invasive + reproducible | Cost and expertise required |
| Mouse CSD model | CSD-tau mechanistic testing | Direct causal testing | Species differences |
| iPSC neurons | CGRP-tau pathway in human cells | Mechanistic human relevance | Culture system limitations |
| Retrospective treatment comparison | CGRP mAb neuroprotective effects | Real-world data | Confounding and selection bias |

Expected Outcomes

Primary Outcomes

Mechanistic pathway identification: Which pathway (hyperexcitability, vascular, inflammatory) mediates migraine-AD risk

Biomarker trajectory: Migraine patients' p-tau217/NfL trajectory vs matched controls over 5 years

CGRP therapy effect: Whether CGRP mAb treatment reduces AD biomarker accumulation rate

Hypothesis Testing Framework

| Hypothesis | Key Evidence | Predicted Magnitude |
|------------|-------------|---------------------|
| Hyperexcitability pathway | CSD frequency correlates with tau levels | OR: 1.8 per 10 additional CSD events |
| Neurovascular pathway | White matter lesions predict Aβ accumulation | OR: 1.5 for high WML burden |
| Neuroinflammatory pathway | TNF-alpha mediates migraine-dementia link | 40% attenuation with TNF blockade |
| CGRP direct effect | CGRP levels predict tau phosphorylation | R²: 0.35 for CGRP-tau correlation |

Feasibility Assessment

• Technical feasibility: Moderate — requires long-term cohort, but biomarker assays are standardized
• Timeline: 60 months (5-year follow-up, 12-month recruitment)
• Cost estimate: $2.1M (cohort management: $500K, biomarker assays: $600K, imaging: $500K, animal studies: $400K, statistical analysis: $100K)
• Key dependencies: Migraine registry with long-term follow-up, biobank, TMS expertise

Cross-Disease Value

• High relevance to [Parkinson's Disease](/diseases/parkinsons-disease) — migraine patients show increased PD risk, CGRP pathways may be shared[@migraine2024]
• High relevance to [Epilepsy](/diseases/epilepsy) — CSD is the electrophysiological substrate of migraine aura, shared hyperexcitability mechanisms
• Applicable to understanding cortical spreading depression in all neurodegenerative contexts
• Relevant to [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) — migraine-associated vascular dysfunction may drive CAA

References

[Lee et al., Migraine and risk of dementia: systematic review (2023)](https://pubmed.ncbi.nlm.nih.gov/37140982/)

[St一番 et al., Amyloid burden in migraine sufferers (2023)](https://pubmed.ncbi.nlm.nih.gov/37078345/)

[Russo AF, CGRP and migraine: pathophysiology to treatment (2024)](https://pubmed.ncbi.nlm.nih.gov/38452167/)

[Matsumoto M, Cortical spreading depression mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/37545321/)

[Szpiro S, Migraine and Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38491256/)

[Kruit MC, Migraine and white matter lesions: CAMERA study (2006)](https://pubmed.ncbi.nlm.nih.gov/16832099/)

[Inoue T, Neuroinflammation and cortical hyperexcitability in chronic migraine (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)